CA2654801C - Quinolinone derivatives and their pharmaceutical compositions - Google Patents

Quinolinone derivatives and their pharmaceutical compositions Download PDF

Info

Publication number
CA2654801C
CA2654801C CA2654801A CA2654801A CA2654801C CA 2654801 C CA2654801 C CA 2654801C CA 2654801 A CA2654801 A CA 2654801A CA 2654801 A CA2654801 A CA 2654801A CA 2654801 C CA2654801 C CA 2654801C
Authority
CA
Canada
Prior art keywords
hydroxy
quinolin
ylamino
indan
diethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2654801A
Other languages
English (en)
French (fr)
Other versions
CA2654801A1 (en
Inventor
Olivier Lohse
Stephanie Monnier
Jean-Louis Reber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2654801A1 publication Critical patent/CA2654801A1/en
Application granted granted Critical
Publication of CA2654801C publication Critical patent/CA2654801C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2654801A 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions Active CA2654801C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613156.9 2006-06-30
GB0613159.3 2006-06-30
GB0613160.1 2006-06-30
GB0613158.5 2006-06-30
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129.4 2006-07-13
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CA2654801A1 CA2654801A1 (en) 2008-01-03
CA2654801C true CA2654801C (en) 2014-08-19

Family

ID=38610531

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2654801A Active CA2654801C (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Country Status (29)

Country Link
US (2) US8198450B2 (enExample)
EP (1) EP2044025B1 (enExample)
JP (1) JP5253392B2 (enExample)
KR (1) KR101402398B1 (enExample)
CN (1) CN101479245B (enExample)
AU (1) AU2007264946B2 (enExample)
BE (2) BE2020C550I2 (enExample)
BR (1) BRPI0713951B8 (enExample)
CA (1) CA2654801C (enExample)
CY (3) CY1113733T1 (enExample)
DK (1) DK2044025T3 (enExample)
ES (1) ES2396987T3 (enExample)
FI (2) FIC20200047I1 (enExample)
FR (2) FR20C1054I1 (enExample)
HR (1) HRP20121074T1 (enExample)
HU (2) HUS2000043I1 (enExample)
IL (1) IL195796A (enExample)
LT (2) LTC2044025I2 (enExample)
LU (2) LUC00185I2 (enExample)
MA (1) MA30540B1 (enExample)
MX (1) MX2008016542A (enExample)
MY (1) MY150468A (enExample)
NO (3) NO341709B1 (enExample)
NZ (1) NZ573292A (enExample)
PL (1) PL2044025T3 (enExample)
PT (1) PT2044025E (enExample)
SI (1) SI2044025T1 (enExample)
WO (1) WO2008000839A1 (enExample)
ZA (1) ZA200809948B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2452965T3 (es) 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法
WO2026027448A1 (en) 2024-07-29 2026-02-05 Inke, S.A. Micronization process of indacaterol acetate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en) 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
ATE421322T1 (de) 2003-04-04 2009-02-15 Novartis Pharma Gmbh Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
CN101142217B (zh) 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
KR101402398B1 (ko) 2014-06-03
CY2020038I1 (el) 2021-03-12
CY2020038I2 (el) 2021-03-12
CY2020041I2 (el) 2021-03-12
SI2044025T1 (sl) 2013-01-31
PT2044025E (pt) 2012-12-17
MX2008016542A (es) 2009-01-19
LTPA2020535I1 (lt) 2020-12-28
ES2396987T3 (es) 2013-03-01
FIC20200050I1 (fi) 2020-12-16
FR20C1063I1 (fr) 2021-01-22
IL195796A (en) 2016-03-31
FR20C1054I1 (fr) 2020-12-25
US20090325912A1 (en) 2009-12-31
JP2009541455A (ja) 2009-11-26
PL2044025T3 (pl) 2013-02-28
AU2007264946A1 (en) 2008-01-03
CN101479245A (zh) 2009-07-08
CA2654801A1 (en) 2008-01-03
EP2044025A1 (en) 2009-04-08
NO2020044I1 (no) 2020-12-07
MA30540B1 (fr) 2009-06-01
US8198450B2 (en) 2012-06-12
LUC00188I2 (enExample) 2024-07-01
LUC00185I2 (enExample) 2024-07-01
NZ573292A (en) 2011-03-31
IL195796A0 (en) 2009-09-01
HUS2000043I1 (hu) 2020-12-28
DK2044025T3 (da) 2013-01-14
JP5253392B2 (ja) 2013-07-31
ZA200809948B (en) 2009-05-25
BE2020C552I2 (enExample) 2026-07-08
HUS2000053I1 (hu) 2020-12-28
KR20090023651A (ko) 2009-03-05
BE2020C550I2 (enExample) 2026-07-08
AU2007264946B2 (en) 2011-01-20
WO2008000839A1 (en) 2008-01-03
EP2044025B1 (en) 2012-10-03
MY150468A (en) 2014-01-30
NO20090312L (no) 2009-01-28
NO341709B1 (no) 2018-01-02
US20120316142A1 (en) 2012-12-13
BRPI0713951A2 (pt) 2012-12-04
NO2020041I1 (no) 2020-11-23
BRPI0713951B8 (pt) 2021-05-25
FIC20200047I1 (fi) 2020-11-27
LTC2044025I2 (lt) 2022-10-10
CN101479245B (zh) 2013-05-22
CY1113733T1 (el) 2016-06-22
LTPA2020538I1 (lt) 2021-01-11
BRPI0713951B1 (pt) 2019-08-13
CY2020041I1 (el) 2021-03-12
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31

Similar Documents

Publication Publication Date Title
AU2004226824B2 (en) Quinoline-2-one-derivatives for the treatment of airways diseases
US20120316142A1 (en) Quinolinone derivatives and their pharmaceutical compositions
US20100010039A1 (en) Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
RU2348646C1 (ru) Полиморфизм додекагидроциклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
AU2005261869B2 (en) Glucocorticoid 16alpha, 17.alpha.-isoxazolidines as anti-inflammatory agents
US20090264461A1 (en) Polymorph of (R)-3- (2-Hydroxy-2, 2-Diphenyl -Acetoxy) -1- (Isoxazol-s-ylcarbamoyl-methyl)-1-Azoni A-Bicyclo-[2.2.2] Octane Bromide
RU2449991C2 (ru) Производные хинолинона и содержащие их фармацевтические композиции
HK1127597B (en) Quinolinone derivatives and their pharmaceutical compositions
EP1878722A1 (en) Quinolinone derivatives and their pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260616